Carcino3D™ technology, developed from patient biopsies and immune cells, creates personalised tumors with specific characteristics and mutations. Tumors are available in different subtypes, including non-small cell, glioblastoma, triple-negative, and adenocarcinoma. They offer formats like 96 or 384 well plates and microfluidic devices for drug testing or can be cryopreserved and shipped. Carcinotech, located in Edinburgh, provides personalised medicine and assay services, with a focus on developing innovative cancer treatments.